Edwards Lifesciences Corp

NYSE:EWUnited States

Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.

Contact Information

Headquarters

One Edwards WayIRVINE, CA, United States 92614

Phone

949-250-2500

Fax

302-655-5049

Executives

Independent Chairman of the Board

Nicholas Valeriani

President

Bernard Zovighian

Chief Financial Officer, Corporate Vice President

Scott Ullem

Senior Vice President, General Manager - Surgical Structural Heart

Wayne Markowitz

Corporate Vice President - Strategy and Corporate Development

Donald Bobo